Aurinia Pharmaceuticals Inc.
AUPH
$15.14
$0.231.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.41% | 22.41% | 24.18% | 32.76% | 24.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.41% | 22.41% | 24.18% | 32.76% | 24.32% |
| Cost of Revenue | 34.11% | 11.99% | 7.62% | -12.57% | -68.88% |
| Gross Profit | 5.75% | 25.47% | 30.13% | 56.79% | 79.93% |
| SG&A Expenses | -38.20% | -42.10% | -57.36% | -26.04% | -11.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -79.69% | 3,288.28% | 207.37% | -56.08% | 72.93% |
| Total Operating Expenses | -21.96% | -13.57% | -31.28% | -24.37% | -20.85% |
| Operating Income | 153.19% | 4,679.82% | 455.86% | 132.73% | 172.24% |
| Income Before Tax | 115.86% | 1,399.05% | 343.25% | 104.44% | 212.61% |
| Income Tax Expenses | -10.07% | -14.95% | 35.99% | -155.77% | 53.36% |
| Earnings from Continuing Operations | 119.87% | 2,879.64% | 317.17% | 105.32% | 206.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 119.87% | 2,879.64% | 317.17% | 105.32% | 206.72% |
| EBIT | 153.19% | 4,679.82% | 455.86% | 132.73% | 172.24% |
| EBITDA | 107.98% | 469.31% | 1,738.77% | 167.17% | 251.27% |
| EPS Basic | 138.68% | 3,090.00% | 325.20% | 105.37% | 206.59% |
| Normalized Basic EPS | 134.31% | 829.73% | 908.33% | 162.86% | 212.52% |
| EPS Diluted | 130.00% | 3,090.00% | 314.48% | 105.37% | 206.27% |
| Normalized Diluted EPS | 131.34% | 811.71% | 884.72% | 160.52% | 210.43% |
| Average Basic Shares Outstanding | -7.86% | -5.90% | -3.54% | -0.52% | 0.14% |
| Average Diluted Shares Outstanding | -6.62% | -4.57% | -0.57% | 3.32% | 1.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |